Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRISPR-Cas12b is a genome editing enzyme and a member of the type V-B CRISPR-Cas system family. It is a dual-RNA-guided endonuclease that functions as a programmable nuclease for targeted DNA editing[3][5]. **Mechanism of action:** Cas12b recognizes and cleaves target DNA sequences guided by crRNA (CRISPR RNA) and tracrRNA components. The enzyme generates double-strand breaks with 6-8 nucleotide 5' sticky ends, which are the longest sticky ends among current CRISPR-Cas systems, promoting non-homologous end joining (NHEJ)-based gene modifications[6]. Cas12b recognizes distal T-rich protospacer adjacent motifs (PAMs), primarily ATTN sequences[5]. **Key advantages:** - Smaller protein size (1,108 amino acids) compared to Cas9 (1,368 amino acids) and Cas12a (1,307 amino acids), making it suitable for viral vector delivery[7] - Higher target specificity and minimal off-target effects compared to Cas9[4][5] - Highly sensitive to mismatches—a single nucleotide mutation in the first 18 nucleotides of the target sequence is sufficient to prevent cleavage[6] - Generates larger deletions (5-15 bp) than other CRISPR systems[5] - Wide temperature and pH stability[4] - Improved stability in human plasma[4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CRISPR-Cas12b.